[HT-01] Hot Topics 01

[HT-01-4] CLARITY AD: A Global Phase 3 Trial of Lecanemab in Early Alzheimer's Disease

Jin Zhou (Eisai, Inc., USA)

Dr. Jin Zhou is Executive Director of Clinical Research in Alzheimer’s Disease and Brain Health at Eisai. She has 20 years of clinical research and pharmaceutical industry experience. At Eisai, she is responsible for clinical programs including AHEAD 3-45 study of lecanemab in preclinical Alzheimer’s Disease and E2814 Arm of DIAN-TU Tau NexGen platform trial, evaluating concurrent treatment of E2814 and lecanemab in Dominantly Inherited Alzheimer’s Disease. She earned her medical degree and completed Neurology training from the Capital University of Medical Sciences in Beijing, China. She completed her PhD in Neuroscience at University of Illinois at Chicago, and postdoc fellowship at Rockefeller University in the United States. Her research interests range from molecular mechanisms to nonclinical /clinical translation to therapeutics of neurodegenerative diseases and stroke. Prior to joining Eisai in 2019, Dr. Zhou held a series of clinical development positions at Daiichi Sankyo, Pfizer, and AstraZeneca.